NeoImmuneTech, Inc.
950220.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$63.43B
Close$
Share Statistics
| Market cap | $63.43 Billion |
|---|---|
| Enterprise Value | $39.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6725.8 |
| Beta | 0.34 |
| Outstanding Shares | 33,625,540 |
Return
| Return on Equity | -43.27% |
|---|---|
| Return on Assets | -32.04% |
| Return on Invested Capital | -43.42% |
Valuation & Multiples
| P/E Ratio | -0.2 |
|---|---|
| PEG | 0.21 |
| Price to Sales | 34.38 |
| Price to Book Ratio | 1.06 |
| Enterprise Value to Revenue | 22.33 |
| Enterprise Value to EBIT | -1.56 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About NeoImmuneTech, Inc.
82 employees
CEO: Luke Yun Suk Oh As a clinical-stage biotechnology firm with a strong focus on T cells, NeoImmuneTech, Inc. is dedicated to creating and marketing innovative immunotherapies. The company's lead product, NT-I7, is a long-acting human IL-7 currently in cli...